Omid Hamid MD
Hematologic Oncology, Melanoma, Complementary and Integrative
Chief, Reasearch & Immuno-Oncology
Join to View Full Profile
2001 Santa Monica BlvdSte 560WSanta Monica, CA 90404
Phone+1 310-582-7900
Fax+1 310-582-7946
Dr. Hamid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2004 - 2005- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2003 - 2004
- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2002 - 2003
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1999 - 2002
Keck School of Medicine of the University of Southern CaliforniaClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2026
Clinical Trials
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Start of enrollment: 2010 Jun 22
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Publications & Presentations
PubMed
- Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.Maryam Kazerani, Simeon Mahov, Joslyn Foley, Noah M Merin, So Yung Choi
Human Vaccines & Immunotherapeutics. 2025-12-01 - 11 citationsLong-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.Theresa Medina, Jason A Chesney, Harriet M Kluger, Omid Hamid, Eric D Whitman
Journal of Clinical Oncology. 2025-11-20 - 2 citationsNeoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-...Georgina V Long, Nitya Nair, Daniel Marbach, Richard A Scolyer, Sabine Wilson
Nature Medicine. 2025-11-01
Journal Articles
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Other
- Mucosal melanomaHamid O, Ariyan C, Carvajal RD
http://www.uptodate.com/contents/mucosal-melanoma
UpToDate, Wolters Kluwer Health - 2012-06-11
Authored Content
- ESMO 2021: Leaving Paris Energized to Return to Patient CareSeptember 2021
Press Mentions
DDx Deep Dive: Special Episode on Melanoma with Omid Hamid, MDOctober 24th, 2025- Understanding Melanoma: Breakthroughs, Risk Factors, and Prevention with Dr. Omid HamidMay 26th, 2025
- Pembrolizumab for Advanced Melanoma: Is It Worth It?May 9th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
